ORKA · Oruka Therapeutics Inc
United States · RS rating 96 · As of 2026-11-03
| Price | 99.55 USD |
|---|---|
| 1-day change | +4.3% |
| RS rating (overall / 1M / 3M / 12M) | 96 / 92 / 72 / 98 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 43 / 50 / 36 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -14.6% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +12.0% |
| Market cap (USD) | $3.4B |